BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3199882)

  • 1. HLA-A11 is associated with poor prognosis in childhood acute lymphoblastic leukemia (ALL).
    Orgad S; Cohen IJ; Neumann Y; Vogel R; Kende G; Ramot B; Zaizov R; Gazit E
    Leukemia; 1988 Dec; 2(12 Suppl):79S-87S. PubMed ID: 3199882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
    Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
    Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia.
    van Wering ER; Beishuizen A; Roeffen ET; van der Linden-Schrever BE; Verhoeven MA; Hählen K; Hooijkaas H; van Dongen JJ
    Leukemia; 1995 Sep; 9(9):1523-33. PubMed ID: 7658722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood.
    Wiersma SR; Ortega J; Sobel E; Weinberg KI
    N Engl J Med; 1991 Mar; 324(12):800-8. PubMed ID: 1997852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxidase-negative and myelomonocytic antigen-positive acute leukemia.
    Okawa H; Nagasawa M; Morio T; Takase K; Tanaka K; Yata J; Dan K; Nomura T; Sakamaki H; Onozawa Y
    Int J Hematol; 1992 Apr; 55(2):165-71. PubMed ID: 1324747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of childhood acute lymphoblastic leukemia (ALL): monoclonal antibodies phenotyping and induction of differentiation in vitro.
    Umiel T; Luria D; Stark B; Cohen IJ; Gozes Y; Kobiler D; Kodman Y; Grunspan A; Dvir A; Yaniv I
    Leukemia; 1988 Dec; 2(12 Suppl):88S-96S. PubMed ID: 3264367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CD10(CALLA)-negative acute lymphoblastic leukemia. A group with a bad prognosis].
    De Salvo L; Plumacher Z; Ríos M; Romero E; Weir J; Gómez O; Salas D
    Invest Clin; 1992; 33(4):147-52. PubMed ID: 1303674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies].
    Ludwig WD; Teichmann JV; Sperling C; Komischke B; Ritter J; Reiter A; Odenwald E; Sauter S; Riehm H
    Klin Padiatr; 1990; 202(4):243-52. PubMed ID: 2203938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential prognosis detected by immunophenotyping in acute lymphoblastic leukemia of childhood with poor prognostic factors.
    Hirata R; Horibe K; Matsuoka H; Ueda R; Iwamura H
    Jpn J Clin Oncol; 1987 Sep; 17(3):229-35. PubMed ID: 2959808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
    Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
    Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotypic and HLA studies in childhood acute lymphoblastic leukemia in Trinidad, West Indies.
    Cameron ES; Labastide WB; Wilson V; Charles W; Holder Y; Reid HF
    Leukemia; 1990 Sep; 4(9):615-9. PubMed ID: 2395381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
    Thomas X; Archimbaud E; Charrin C; Magaud JP; Fiere D
    Leukemia; 1995 Feb; 9(2):249-53. PubMed ID: 7532767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunophenotyping of acute lymphoblastic leukemia in Mexican children].
    Paredes-Aguilera R; Romero-Guzmán L; López-Santiago N; Bravo-Lindoro A; Correa-González C; Joly-Linero R; Nieto-Martínez S; del Campo-Martínez A
    Sangre (Barc); 1999 Jun; 44(3):188-94. PubMed ID: 10481579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.
    Clavell LA; Gelber RD; Cohen HJ; Hitchcock-Bryan S; Cassady JR; Tarbell NJ; Blattner SR; Tantravahi R; Leavitt P; Sallan SE
    N Engl J Med; 1986 Sep; 315(11):657-63. PubMed ID: 2943992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical features of B-precursor childhood acute lymphoblastic leukemia showing CD2 and/or E-rosette co-expression.
    Cantù-Rajnoldi A; Putti MC; Schirò R; Biondi A; Cattoretti G; Valeggio C; Castagni M; Basso G
    Haematologica; 1992; 77(5):384-91. PubMed ID: 1362385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.